IRCT20210913052453N1CompletedPhase 2
Administration of Zinc-Chelating Agents (intravenuosly CaNa2EDTA) in COVID-19 Patients: A pilot study
Asadabad University of Medical Sciences0 sites50 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to no limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with Covid-19 admitted to the Intensive Care Unit (ICU)
- •Patients with Covid-19 with respiratory distress
Exclusion Criteria
- •insulin-dependent diabetic patients
- •Patients with urinary tract disorders
- •Patients with cardiovascular system disorders
Investigators
Similar Trials
Completed
Phase 3
Zinc in addition to antibiotics for treating newborn babies with sepsisCTRI/2017/02/007966Translational Health Science and Technology Institute2,913
Recruiting
Not Applicable
The effects of oral zinc syrup in the treatment of acute diarrhea in childreAcute diarrhea patientsMedian time to recoveryStool frequencyAcute diarrheaTCTR20160114002an Hospital224
Completed
Not Applicable
sefulness of zinc preparation administration in zinc deficiency dialysis patientsJPRN-UMIN000042511Kawashima Hospital Group100
Recruiting
Not Applicable
The study for usefullness of zinc administration in patients with chronic liver diseaseschronic liver diseasesJPRN-UMIN000032023Osaka-Rosai Hospital200
Completed
Phase 2
zinc supplement for diarrheaTCTR20190423004Srinakharinwirot University80